Labetuzumab
Modify Date: 2024-01-08 17:28:47
Labetuzumab structure
|
Common Name | Labetuzumab | ||
|---|---|---|---|---|
| CAS Number | 219649-07-7 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of LabetuzumabLabetuzumab is a humanised anti-carcinoembryonic antigen (CEA) monoclonal antibody that inhibits tumour growth and sensitises human medullary thyroid cancer xenografts to Dacarbazine chemotherapy[1]. |
| Name | Labetuzumab |
|---|
| Description | Labetuzumab is a humanised anti-carcinoembryonic antigen (CEA) monoclonal antibody that inhibits tumour growth and sensitises human medullary thyroid cancer xenografts to Dacarbazine chemotherapy[1]. |
|---|---|
| Related Catalog | |
| Target |
CEA[1]. |
| In Vivo | Labetuzumab (0.5 mg/rat; i.v.; single) inhibits tumor growth in vivo[1]. Animal Model: Female nu/nu mice (6 to 8-week-old; inject TT cells)[1]. Dosage: 0.5 mg/rat Administration: Intravenous injection; single (1 day post-tumor cell injection) Result: Significantly delaied growth of tumor, and led to 64%-70% inhibition of tumor size between days 32 and 60. |
| References |
| No Any Chemical & Physical Properties |